• Ting Liao, Li Li, and Liya Wang.
• Department of Obstetrics and Gynecology, Chongqing General Hospital, Chongqing, China.
• Medicine (Baltimore). 2021 Dec 23; 100 (51): e28376e28376.

BackgroundThe impact of bevacizumab (an anti-vascular endothelial growth factor therapy) remains uncertain, which has been the focus of studies on the management of ovarian cancer (OC). We performed a protocol for systematic review and meta-analysis to assess the efficacy and safety of bevacizumab combined with chemotherapy in OC.MethodsThe presentation of methods and results in this systematic review was performed according to the evaluation guidelines for health care interventions provided in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocol. This study will use the Cochrane Library, Web of Science, PubMed, Embase, Allied and Complementary Medicine Database, China Biomedical Literature Database, China National Knowledge Infrastructure, China Science and Technology Journal Database, Wanfang Database, and Ongoing Clinical Trials Database. The risk of bias of included studies is estimated by taking into consideration the characteristics including random sequence generation, allocation concealment, blinding of patients, blinding of outcome assessment, completeness of outcome data, selective reporting, and other bias by Cochrane Collaboration's tool. All analyses were performed with Review Manager (RevMan) software, version 5.3.ResultsThe results of this systematic review and meta-analysis will be published in a peer-reviewed journal.ConclusionBevacizumab combined with chemotherapy may improve progression-free survival and overall survival in patients with OC.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

26 keywords...

hide…